、生物技术类药物、神经系统药物、抗感染药物和复方药物为排名居 TOP 5 的治疗领域。其中，癌症仍是药品研发的核心领域，抗癌/抗肿瘤药物数量呈现显著增长态势，数量...，与 2015 年数据进行对比，可反映不同治疗类别在研药物数量的变化情况。从治疗类别 TOP 25 排名中发现，一般抗癌药 (在研药物 2071 个)、免疫类

to neurodegeneration. Nat Neurosci 26, 942–954 (2023). https

研究是一项全球多中心、随机、开放的非劣效 III 期临床试验，共纳入 954 名既往未治疗的不可切除的 HCC 患者，其中包含近 300 例中国（大陆、台湾省

，954（93％）名丙型肝炎病毒抗体阳性，而且24％丙型肝炎病毒阳性的患者分离出了HBV核心抗体阳性（24％VS2％;P<0.0001;比值比为12.5

(51%)患者均为男性，诊断时平均年龄为42.1岁，开始治疗时的平均年龄约为50年。多数患者(1,131例)曾经治疗过该病，其中954例曾接受手术治疗。多数患者生活

例，年龄6 岁～83 岁，症状缓解出院954 例，死亡4 例。2004 年门诊患者3933 例。 护理干预方法

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

Payments by RMB (CNY)

• Payment by telegraphic transfer in CNY must be made to:
  A/C Name:
  A/C No.: 720-031103-001
  Beneficiary Bank:
  Bank Address: No. 1000 Lujiazui Rind Road,
  Pudong, Shanghai 200120, P.R. China
  Bank Swift Code: HSBCCNSH

CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.

多中心随机对照临床研究。该研究是一项与索拉非尼头对头比较的非劣效试验，入组 uHCC 患者 954 例，其中中国（含大陆、台湾省、香港特区）患者近 300 例...做得非常好，这也是它能取得成功的一个重要依据。乐伐替尼的成功将改变肝癌临床实践秦教授提到，乐伐替尼 III 期临床研究纳入样本 954 例，这样一个大样本研究的

本期「TOP list ·月度案例评选」是基于 6 月在丁香园医院汇平台上发布的文章，根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库，供行业宣传人士参考学习，也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10排名医院

本期「TOP list ·月度案例评选」是基于 6 月在丁香园 医院汇 平台上发布的文章，根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库，供行业宣传人士参考学习，也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10

「借花献佛」，和大家分享下推荐最多的 10 本 「案头必备」和 10 本 「床头必备」好书。一、案头必备TOP 1. 实用内科学推荐理由：中国医学界唯一一部畅销...出版一次，已出至第14版，可及时反映国内外进展，是内科领域各级学科医师的 「不二宝典」。TOP 2. 坎贝尔骨科手术学推荐理由：国际权威骨科经典著作，内含众多

2013年岁末已至，回首这一年，一批「重磅炸弹」级新药的诞生，使得生物制药成为全球医药领域的一个焦点。Top1 默克...晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2 糖尿病治疗的新突破强生和Evotec公司共同开发

2013年岁末已至，回首这一年，一批"重磅炸弹"级新药的诞生，使得生物制药成为全球医药领域的一个焦点。Top...积极的数据。制药巨头正准备将晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2：糖尿病治疗的新突破强生和Evotec公司

, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster

。【报名回执】访问此链接填写报名回执（https://www.wjx.top/jq/80710449.aspx）【咨询请联系】QQ 号：2814500767邮箱